CN108289901B - 用于预防和治疗眼痛的氨基次膦酸衍生物 - Google Patents

用于预防和治疗眼痛的氨基次膦酸衍生物 Download PDF

Info

Publication number
CN108289901B
CN108289901B CN201680070092.8A CN201680070092A CN108289901B CN 108289901 B CN108289901 B CN 108289901B CN 201680070092 A CN201680070092 A CN 201680070092A CN 108289901 B CN108289901 B CN 108289901B
Authority
CN
China
Prior art keywords
compound
formula
group
pain
ophthalmic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680070092.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108289901A (zh
Inventor
H.波雷斯
M.沃姆
S.梅利克帕萨达尼安兹
A.雷奥克斯-勒戈亚齐戈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhiteng Greater China Co ltd
Original Assignee
Pharmaleads SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaleads SA filed Critical Pharmaleads SA
Priority to CN202010893476.8A priority Critical patent/CN112121008A/zh
Publication of CN108289901A publication Critical patent/CN108289901A/zh
Application granted granted Critical
Publication of CN108289901B publication Critical patent/CN108289901B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680070092.8A 2015-11-30 2016-11-30 用于预防和治疗眼痛的氨基次膦酸衍生物 Active CN108289901B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010893476.8A CN112121008A (zh) 2015-11-30 2016-11-30 用于预防和治疗眼痛的氨基次膦酸衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1561598A FR3044227B1 (fr) 2015-11-30 2015-11-30 Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
FR1561598 2015-11-30
PCT/EP2016/079285 WO2017093322A1 (fr) 2015-11-30 2016-11-30 Dérivés aminophosphiniques pour la prévention et le traitement des douleurs oculaires

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010893476.8A Division CN112121008A (zh) 2015-11-30 2016-11-30 用于预防和治疗眼痛的氨基次膦酸衍生物

Publications (2)

Publication Number Publication Date
CN108289901A CN108289901A (zh) 2018-07-17
CN108289901B true CN108289901B (zh) 2021-05-04

Family

ID=55346018

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010893476.8A Pending CN112121008A (zh) 2015-11-30 2016-11-30 用于预防和治疗眼痛的氨基次膦酸衍生物
CN201680070092.8A Active CN108289901B (zh) 2015-11-30 2016-11-30 用于预防和治疗眼痛的氨基次膦酸衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010893476.8A Pending CN112121008A (zh) 2015-11-30 2016-11-30 用于预防和治疗眼痛的氨基次膦酸衍生物

Country Status (15)

Country Link
US (2) US20180344753A1 (enExample)
EP (1) EP3383403B1 (enExample)
JP (1) JP6889176B2 (enExample)
KR (1) KR102657652B1 (enExample)
CN (2) CN112121008A (enExample)
BR (1) BR112018010007A2 (enExample)
CA (1) CA3006365A1 (enExample)
DK (1) DK3383403T3 (enExample)
ES (1) ES2773148T3 (enExample)
FR (1) FR3044227B1 (enExample)
IL (1) IL259562B (enExample)
MX (1) MX382921B (enExample)
TW (1) TWI729039B (enExample)
WO (1) WO2017093322A1 (enExample)
ZA (1) ZA201804037B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US11090317B2 (en) * 2017-03-09 2021-08-17 Pharmaleads Aminophosphinic derivatives for preventing and treating eye inflammation
FR3063635B1 (fr) * 2017-03-09 2019-06-07 Pharmaleads Derives aminophosphiniques pour la prevention et le traitement de l'inflammation oculaire
FR3104581B1 (fr) * 2019-12-11 2021-11-26 Pharmaleads Procédé de préparation industrielle du sel disodique de ((2S)-3-([1,1'-biphenyl]-4-yl)-2-((hydroxy((1R)-1-(((1-(isobutyryloxy)ethoxy)carbonyl)amino)ethyl)phosphoryl) methyl)propanoyl)-L-alanine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
FR2755135B1 (fr) * 1996-10-25 2002-12-27 Inst Nat Sante Rech Med Nouveaux derives d'(alpha-aminophosphino)peptides, leur procede de preparation et les compositions qui les contiennent
JP2001506652A (ja) * 1996-12-16 2001-05-22 アルコン ラボラトリーズ，インコーポレイテッド 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用
FR2777780B1 (fr) * 1998-04-22 2001-05-04 Inst Nat Sante Rech Med Derives d'(alpha-aminophosphino) peptides, leur procede de preparation et les compositions qui les contiennent
FR2934267B1 (fr) * 2008-07-23 2010-08-13 Pharmaleads Derives aminophosphiniques utiles dans le traitement de la douleur
FR2934627B1 (fr) 2008-07-29 2010-08-13 Paul Marie Bernard Dispositif de positionnement et de calage d'un garde corps escamotable sur plateforme support de banches
CA2901208A1 (en) * 2013-02-13 2014-08-21 Novartis Ag Topical ocular analgesic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
（"Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain";Bernard P. Roques et al.;《Nature Review Drug Discovery》;20120430;第11卷;摘要，第299页图3，第302页Box1，第306页左栏第1段 *

Also Published As

Publication number Publication date
MX2018006580A (es) 2018-08-01
CN112121008A (zh) 2020-12-25
EP3383403B1 (fr) 2019-12-25
BR112018010007A2 (pt) 2018-11-21
JP6889176B2 (ja) 2021-06-18
IL259562B (en) 2020-08-31
US10688113B2 (en) 2020-06-23
FR3044227B1 (fr) 2017-11-24
TW201726146A (zh) 2017-08-01
TWI729039B (zh) 2021-06-01
KR20180095555A (ko) 2018-08-27
FR3044227A1 (fr) 2017-06-02
WO2017093322A1 (fr) 2017-06-08
ZA201804037B (en) 2020-07-29
DK3383403T3 (da) 2020-03-16
IL259562A (en) 2018-07-31
MX382921B (es) 2025-03-13
KR102657652B1 (ko) 2024-04-15
HK1259181A1 (zh) 2019-11-29
US20180344753A1 (en) 2018-12-06
CA3006365A1 (fr) 2017-06-08
CN108289901A (zh) 2018-07-17
US20190167701A1 (en) 2019-06-06
EP3383403A1 (fr) 2018-10-10
ES2773148T3 (es) 2020-07-09
JP2018536714A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
AU2021218212B2 (en) Compositions and methods for treating pterygium
US6294553B1 (en) Method for treating ocular pain
AU2001238313A1 (en) Method for treating ocular pain
US10688113B2 (en) Methods of treating eye pain with aminophosphinic derivatives
EP0630240B1 (en) Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists
HK40042434A (en) Aminophosphinic derivatives for preventing and treating eye pain
JP7628098B2 (ja) エピナスチン又はその塩を含有する花粉破裂抑制剤
JP2023067982A (ja) 眼の炎症を予防及び治療するためのアミノホスフィン誘導体
HK1259181B (en) Aminophosphinic derivatives for preventing and treating eye pain
WO2023137059A1 (en) Topical naltrexone as a treatment for dry eye
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
US8853257B2 (en) Succinimide derivatives as ocular hypotensive agents
BR112017025122B1 (pt) Uso de nintedanib para tratar pterígio
KR20080068881A (ko) 안압 강하제인 숙신이미드 유도체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230506

Address after: Room D, 4F, Willie Building, 97 Wellington Street, Central, Hong Kong, China

Patentee after: Zhiteng Greater China Co.,Ltd.

Address before: Paris France

Patentee before: PHARMALEADS